Related Experiment Video

Updated: Nov 5, 2025

Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control
05:41

Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control

Published on: December 16, 2022

3.9K

Effect of aspirin on short-term outcomes in hospitalized patients with COVID-19

Aditya Sahai1, Rohan Bhandari1,2, Matthew Godwin2

  • 1Section of Vascular Medicine, Department of Cardiovascular Medicine; Heart, Vascular & Thoracic Institute, Cleveland Clinic, Cleveland, OH, USA.

Vascular Medicine (London, England)
|May 19, 2021
PubMed

Insights

Aspirin did not prevent blood clots or death in COVID-19 patients. Further research is needed to understand the distinct mechanisms of thrombosis in COVID-19 and the role of platelets.

Area of Science:

  • Infectious Diseases
  • Cardiovascular Medicine
  • Hematology

Background:

  • Coronavirus disease 2019 (COVID-19) is associated with a higher risk of thrombotic events.
  • The specific role of platelets in COVID-19-related thrombosis and the effectiveness of antiplatelet therapies remain unclear.

Purpose of the Study:

  • To investigate whether aspirin, an antiplatelet agent, can reduce the risk of myocardial infarction, cerebrovascular accident, and venous thromboembolism in patients with COVID-19.
  • To explore the impact of aspirin and nonsteroidal anti-inflammatory drugs (NSAIDs) on thrombotic outcomes in the context of COVID-19.

Main Methods:

  • Evaluation of 22,072 symptomatic patients tested for COVID-19.
  • Propensity-matched analyses were conducted to compare outcomes between patients treated with aspirin or NSAIDs and those who were not.

Main Results:

  • Neither aspirin nor NSAIDs demonstrated an effect on mortality rates in patients with COVID-19.
  • Aspirin treatment did not appear to prevent thrombotic events or reduce mortality in the studied COVID-19 patient cohort.

Conclusions:

  • Aspirin is not effective in preventing thrombosis and death in COVID-19.
  • The mechanisms underlying thrombosis in COVID-19 appear distinct from those targeted by aspirin.
  • Further investigation is required to elucidate the role of platelets in SARS-CoV-2-mediated thrombosis.

Keywords:
ACE2COVID-19SARS-CoV-2TMPRSS2plateletsthrombosis

More Related Videos

Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment08:36

Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment

Published on: April 19, 2024

848
Optimized Management of Endovascular Treatment for Acute Ischemic Stroke09:21

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke

Published on: January 18, 2018

12.3K

Related Concept Videos

Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
70
Acute Coronary Syndrome V: Nursing Management01:26

Acute Coronary Syndrome V: Nursing Management

Nursing Assessment:Nursing management of acute coronary syndrome (ACS) involves taking the patient's history, focusing on primary complaints such as chest pain, dyspnea, and excessive sweating (diaphoresis), as well as other symptoms like back or jaw pain, nausea, vomiting, palpitations, dizziness, and fatigue. The nurse also reviews the patient's history of cardiac events, risk factors such as hypertension, diabetes, smoking, family history, and current medications.In the objective assessment,...
98
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
801
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
62
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
85
Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
208